ClinicalTrials.gg
Not yet recruitingNCT07243158Updated Nov 21, 2025

Randomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation

An interventional study of DragonFly System and Drug in Mitral Regurgitation Functional, sponsored by Hangzhou Valgen Medtech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Hangzhou Valgen Medtech Co., Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
17th of 40
148 · median 127
Started
2025
with 8 others
No phase
36 of 57
29 open now
Primary completion
2027-06
later than 28 of 45 live
Registered
45th of 57
by date
Lead sponsor
4 of 57
Hangzhou Valgen Medtech Co., Ltd

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 17th largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2025, is one of 36 with no phase, reaches primary completion later than 28 of the 45 other live ones, and was the 45th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after adequate treatment.

Read the detailed description

This study is a prospective, multicenter, randomized controlled design. Patients are chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment. After signing an informed consent form, subjects in the experimental group will undergo the transcatheter mitral valve repair procedure using the DragonFly™ Transcatheter Mitral Valve Clip System . According to the investigator's discretion, all subjects in the treatment group will continue to receive maximally tolerated guideline-directed medical therapy (GDMT). Subjects in the control group will also continue maximally tolerated GDMT as determined by the investigator. After completing the 12-month follow-up, crossover to the treatment group will be permitted.

All subjects were followed up before discharge (excluding the control group), and 30 days, 6 months, 12 months, and 24 months after treatment. Subjects in the experimental group and those who crossed over to the experimental group underwent extended clinical follow-up for 3, 4, and 5 years.

03

Conditions studied

  • Mitral Regurgitation Functional
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) Age ≥ 18 yrs. 2) Symptomatic functional mitral regurgitation (FMR) (≥3+) due to ischemic or non-ischemic cardiomyopathy

  • Transseptal catheterization and femoral vein access is determined to be feasible.
  • The subject or subject's legal representative has been informed of the nature of the trial, willing to accept the experimental tests, and has provided written .

Exclusion criteria

Exclusion Criteria:

1) Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2)Echocardiography revealed severe restriction of leaflet motion due to tethering.

3) The presence of other severe heart valve disease requiring surgical intervention.

  • Currently participating in an drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  • In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Randomized - Device Group

    This group is allocated to use DragonFly System for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.

    Device: DragonFly System · Drug: Drug

  • Active comparator
    Randomized - Control Group

    This group will continue to be managed on medical therapy, per physician discretion

    Device: DragonFly System · Drug: Drug

Interventions

  • DeviceDragonFly System

    This group is allocated to use DragonFly System for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.

  • DrugDrug

    This group will continue to be managed on medical therapy, per physician discretion

06

What researchers measure

Primary outcomes

  1. Clinical success at 12 months after the procedure

    The rate of the composite endpoint of freedom from all-cause mortality, hospitalization for heart failure, NYHA improved \<1 class and MR \> 2+ at 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Mitral regurgitation severity

    Percentage of patients with mitral regurgitation of 2+ or less.

    Time frame: 30 days, 6 months, 12 months

  2. Recurrent heart failure (HF) hospitalizations

    Number of patients with incidence of re-hospitalizations for heart failure after Dragonfly implantation.

    Time frame: 30 days, 6 months, 12 months

  3. NYHA Class

    Number of patients with New York Heart Association (NYHA) Function Class I or II.

    Time frame: 30 days, 6 months, and 12 months

  4. Change in 6 minutes walk test distance

    Improvement in 6 Minute Walk Test distance at 12 months over baseline.

    Time frame: 12 months

  5. Quality of life improvement

    Improvement in quality of life (QoL) at 12 months over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Time frame: 12 months

  6. Left Ventricular End Diastolic Volume (LVEDV)

    Left Ventricular End Diastolic Volume (LVEDV) as determined by the core echocardiography laboratory from a transthoracic echocardiogram (TTE).

    Time frame: 12 months

  7. Acute procedural success(only for experimental group)

    Successful in Dragonfly implantation, and residual MR of 2+ or less at discharge. An echocardiography echocardiogram at 30 days can be accepted if the discharge image was not available or hard to interpret. A death before discharge or a re-operation of mitral valve prior to 30 days is defined as acute procedure failure.

    Time frame: Immediately after procedure, Discharge: The day after the patient's exit from the cardiac catheterization laboratory

  8. Acute device success(only for experimental group)

    One or more Dragonfly devices are successfully delivered and released, edge-to-edge leaflet repair confirmed by echocardiogram, and successfully withdrawal of the delivery catheter.

    Time frame: Immediately after procedure

Other outcomes

  1. Incidence of adverse events

    MAE is defined as a combined clinical endpoint of single leaflet device attachment (SLDA), device embolization, endocarditis requiring surgery, mitral stenosis confirmed by the echocardiographic core laboratory requiring surgical intervention, left ventricular assist device (LVAD) implantation, heart transplantation, and nonelective cardiovascular surgery for device or procedure-related adverse events occurring after transseptal catheterization.(only for experimental group)

    Time frame: 12 months

  2. Incidence of major adverse events (MAEs)

    MAE is defined as a combined clinical endpoint of death, stroke, myocardial infarction, and nonelective cardiovascular surgery for device or procedure-related adverse events occurring after transseptal catheterization.(only for experimental group)

    Time frame: 30 Days

  3. All-cause mortality

    Percentage of all-cause death includes cardiac death, non-cardiac death, and death from unknown causes.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 18 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartEst.
Dec 30, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2030
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07243158
Lead sponsor
Hangzhou Valgen Medtech Co., Ltd
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 30, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 21, 2025

Study contacts

Bo Liu
Contact
bo.liu@valgenmed.com
+86 13001980902
Xiaoxu Yang
Contact
xiaoxu.yang@valgenmed.com
+86 18910330079
Jianan Wang
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion